Search all trials

Find therapies in clinical trials near you – page 7

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Marstacimab

Contact Research Centre

Atrial fibrillation+2

Recruiting

Registered drugNo placebo

Study on Edoxaban for Patients with Atrial Fibrillation and Coronary Syndrome Undergoing PCI

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Registered drugNo placebo

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Asparaginase

Contact Research Centre

Prostate cancer

Recruiting

Registered drugNo placebo

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Apalutamide

Contact Research Centre

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Italy

Participants:0–17 years
Substances:Marstacimab

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Registered drug

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Alogliptin

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Investigational

Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Italy

Participants:18–64 years · 65+ years

Contact Research Centre

Metastatic renal cell carcinoma

Not yet recruiting

Registered drugNo placebo

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Axitinib

Contact Research Centre

Chronic graft versus host disease

Not yet recruiting

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Optic ischaemic neuropathy

Not yet recruiting

Investigational

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Cenegermin

Contact Research Centre

Non-small cell lung cancer+1

Not yet recruiting

InvestigationalNo placebo

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years

Contact Research Centre

Focal segmental glomerulosclerosis

Not yet recruiting

Registered drug

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan

Contact Research Centre

Find therapies in clinical trials near you – page 7

211 trials match your criteria

Factor VIII deficiency+1

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

Atrial fibrillation+2

Study on Edoxaban for Patients with Atrial Fibrillation and Coronary Syndrome Undergoing PCI

Acute lymphocytic leukaemia

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Prostate cancer

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Factor VIII deficiency+1

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

Type 2 diabetes mellitus

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Arteriosclerosis

Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Metastatic renal cell carcinoma

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Chronic graft versus host disease

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Optic ischaemic neuropathy

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-small cell lung cancer+1

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

Focal segmental glomerulosclerosis

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.